EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Axel,Heidenreich ^[1] ; Patrick J,Bastian ^[2] ; Joaquim,Bellmunt ^[3] ; Michel,Bolla ^[4] ; Steven,Joniau ^[5] ; Theodor,van der Kwast ^[6] ; Malcolm,Mason ^[7] ; Vsevolod,Matveev ^[8] ; Thomas,Wiegel ^[9] ; Filiberto,Zattoni ^[10] ; Nicolas,Mottet ^[11] ; European Association of Urology

作者单位： Department of Urology, RWTH University, Aachen, Germany. Electronic address: aheidenreich@ukaachen.de. ^[1] Department of Urology, Klinikum Golzheim, Düsseldorf, Germany. ^[2] Department of Medical Oncology, University Hospital Del Mar, Barcelona, Spain. ^[3] Department of Radiation Therapy, CHU Grenoble, Grenoble, France. ^[4] Department of Urology, University Hospital, Leuven, Belgium. ^[5] Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands. ^[6] Department of Oncology and Palliative Medicine, Velindre Hospital, Cardiff, UK. ^[7] Department of Urology, Russian Academy of Medical Science, Cancer Research Center, Moscow, Russia. ^[8] Department of Radiation Oncology, University Hospital, Ulm, Germany. ^[9] Department of Urology, Santa Maria Della Misericordia Hospital, Udine, Italy. ^[10] Department of Urology, University Hospital St Etienne, France. ^[11]

关键词 Abiraterone Androgen deprivation Chemotherapy Denosumab Docetaxel EAU guidelines Enzalutamide Follow-up Prostate cancer Review Salvage radiation therapy Salvage radical prostatectomy Zoledronic acid